US EditionInhibition of PI3K alpha sensitizes ovarian cancer carrying the PIK3CA mutation to conventional chemotherapy - Toulouse Cancer Research Center
Summary by CRCT - Centre De Recherches en Cancérologie De Toulouse
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Inhibition of PI3K alpha sensitizes ovarian cancer carrying the PIK3CA mutation to conventional chemotherapy. PI3K channel, tumor cell aggregates, resistance to treatment, Targeted therapies, BYL-719/Alpelisib, cisplatin, Combination therapies, Mesenchymal stem cells.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
